Christelle Remy‐Ziller

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

Patricia Kleinpeter, Laetitia Fend, Christine Thioudellet et al. · OncoImmunology · 2016 · 95 citations · Full text

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment

Laetitia Fend, Christelle Remy‐Ziller, Johann Foloppe et al. · OncoImmunology · 2015 · 33 citations · Full text

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Christelle Remy‐Ziller, Christine Thioudellet, Julie Hortelano et al. · Human Vaccines & Immunotherapeutics · 2017 · 33 citations · Full text

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1

Patricia Kleinpeter, Christelle Remy‐Ziller, Eline Winter et al. · Journal of Virology · 2019 · 24 citations · Full text

Immunology, Viral Pathogenesis, Immunodominance +18

Immunological Characterization of a Modified Vaccinia Virus Ankara Vector Expressing the Human Papillomavirus 16 E1 Protein

Christelle Remy‐Ziller, Claire Germain, Anita Spindler et al. · Clinical and Vaccine Immunology · 2013 · 18 citations · Full text